Siltuximab for Castleman's disease: a real-world study
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial is looking back at the medical records of people with a rare condition called Castleman's disease to see how well the drug Siltuximab worked for them in everyday hospital care, not in a research setting. The goal is to learn more about how safe and effective the drug can be for patients in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a certain type of Castleman's disease called relapsed or refractory (came back or didn't respond to treatment) multicentric Castleman's disease.
- You do not have HIV or HHV-8 infection.
- You were treated with Siltuximab between July 2016 and April 2022.
- You are age 18 or older.
- You are willing to let the researchers look at your medical records (or a legal representative can agree for you).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called nintedanib for people with a rare condition called Unicentric Castleman disease (one area of lymph nodes affected) that cannot be fully removed by surgery. The goal is to see if nintedanib can help shrink the tumor or control symptoms.
This trial is a worldwide registry that collects basic medical information from people diagnosed with Castleman disease. It helps researchers learn about real-world care and outcomes across different ages and care settings.
This trial tests a drug called loncastuximab tesirine for people with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that has come back or not responded after CAR-T cell therapy. It aims to see if the drug can help when other treatments have stopped working.
This trial tests the drug ruxolitinib for people with idiopathic multicentric Castleman disease (iMCD) whose symptoms are not well controlled by standard anti-IL-6 therapy. Ruxolitinib is a pill taken by mouth that may help reduce inflammation and improve symptoms.
This trial tests a drug called siltuximab to see if it can help treat a type of lung rejection called antibody-mediated rejection (AMR) in people who have had a lung transplant. You may be eligible if you are currently hospitalized for AMR and are already planning to receive standard treatments.
This trial tests if the drug Siltuximab can help control side effects (CRS and ICANS) that sometimes happen after CAR-T treatment for multiple myeloma. It may help patients who develop these symptoms.
Hear when a new Castleman Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.